Articles related to CARDIOVASCULAR EVENTS

Post-trial analysis reveals a 13% relative reduction in cardiovascular death and kidney disease progression risk, though this benefit primarily manifests in the first 12 months after treatment discontinuation.

A multicenter trial of 7,062 post-MI patients found that colchicine therapy, despite reducing C-reactive protein levels by 1.28 mg/L, did not significantly impact the composite outcome of cardiovascular death, recurrent MI, stroke, or unplanned revascularization over 3 years of follow-up.

A landmark analysis shows that physiology-guided complete revascularization reduced adverse outcomes by approximately 25% compared to culprit-only strategy across both STEMI and NSTEMI patients.

Analysis of 285,680 patients shows a 1.03-1.38% reduction in cumulative mortality with rosuvastatin compared to atorvastatin, alongside varying risks for cardiovascular events, liver outcomes, and diabetes.

In this multicenter trial of 901 patients with asymptomatic severe aortic stenosis, early TAVR intervention reduced the composite endpoint of death, stroke, or unplanned cardiovascular hospitalization by 50% compared to clinical surveillance.

Clinical research demonstrates that erythritol consumption increases blood levels by more than 1,000 times and enhances platelet responsiveness in healthy volunteers, potentially elevating cardiovascular risk in susceptible populations.